How to avoid false con­clu­sions: FDA fi­nal­izes long-await­ed guid­ance on mul­ti­ple end­points in clin­i­cal tri­als

The FDA on Thurs­day fi­nal­ized guid­ance, first draft­ed in 2017, that will help spon­sors bet­ter un­der­stand FDA’s think­ing about the prob­lems posed by mul­ti­ple end­points in the analy­sis and in­ter­pre­ta­tion of clin­i­cal tri­al re­sults, and how these prob­lems can be bet­ter man­aged.

The 26-page guid­ance fea­tures var­i­ous strate­gies for group­ing and or­der­ing end­points for analy­sis and ap­ply­ing sta­tis­ti­cal meth­ods for man­ag­ing mul­ti­plic­i­ty to con­trol the chance of mak­ing er­ro­neous con­clu­sions about a drug’s ef­fects.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER